Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

Huntington's disease (HD) is an inherited, progressive neurological disorder that is caused by a CAG/polyglutamine repeat expansion and for which there is no effective therapy. Recent evidence indicates that transcriptional dysregulation may contribute to the molecular pathogenesis of this disease. Supporting this view, administration of histone deacetylase (HDAC) inhibitors has been shown to rescue lethality and photoreceptor neurodegeneration in a Drosophila model of polyglutamine disease. To further explore the therapeutic potential of HDAC inhibitors, we have conducted preclinical trials with suberoylanilide hydroxamic acid (SAHA), a potent HDAC inhibitor, in the R6/2 HD mouse model. We show that SAHA crosses the blood–brain barrier and increases histone acetylation in the brain. We found that SAHA could be administered orally in drinking water when complexed with cyclodextrins. SAHA dramatically improved the motor impairment in R6/2 mice, clearly validating the pursuit of this class of compounds as HD therapeutics.

[1]  R. Mott,et al.  Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation , 1997, Nature Genetics.

[2]  S. Hersch,et al.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease , 2000, Nature Medicine.

[3]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[4]  C. Craddock,et al.  The T-lineage-affiliated CD2 gene lies within an open chromatin environment in acute promyelocytic leukemia cells. , 2002, Cancer research.

[5]  He Li,et al.  Interaction of Huntington Disease Protein with Transcriptional Activator Sp1 , 2002, Molecular and Cellular Biology.

[6]  P. Marks,et al.  Inhibitors of histone deacetylase are potentially effective anticancer agents. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  I. Kanazawa,et al.  Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription , 2000, Nature Genetics.

[8]  S. Wolfensohn,et al.  Handbook of Laboratory Animal Management and Welfare , 1994 .

[9]  P. Marks,et al.  A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  P. Marks,et al.  Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). , 1999, Anticancer research.

[11]  S. W. Davies,et al.  Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. Housman,et al.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  K. Fischbeck,et al.  Histone deacetylase inhibitors reduce polyglutamine toxicity , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Y. Benjamini,et al.  More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.

[15]  P. Marks,et al.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  C A Ross,et al.  Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity , 2001, Science.

[17]  Ole A. Andreassen,et al.  Therapeutic Effects of Coenzyme Q10 and Remacemide in Transgenic Mouse Models of Huntington's Disease , 2002, The Journal of Neuroscience.

[18]  C A Ross,et al.  Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. , 2000, Human molecular genetics.

[19]  F. Hirayama,et al.  Cyclodextrin Drug Carrier Systems. , 1998, Chemical reviews.

[20]  D. Housman,et al.  Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila , 2001, Nature.

[21]  W. Klunk,et al.  Inhibition of Polyglutamine Aggregation in R6/2 HD Brain Slices—Complex Dose–Response Profiles , 2001, Neurobiology of Disease.

[22]  Mark Turmaine,et al.  Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.

[23]  P. Marks,et al.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.

[24]  J. Olson,et al.  Altered transcription in yeast expressing expanded polyglutamine , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Ole A. Andreassen,et al.  Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease , 2000, The Journal of Neuroscience.

[26]  C. Blakemore,et al.  Environmental enrichment slows disease progression in R6/2 Huntington's disease mice , 2002, Annals of neurology.

[27]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[28]  R A Rifkind,et al.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. , 2000, Cancer research.

[29]  D. Housman,et al.  Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  E. Wanker,et al.  Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients. , 2001, Human molecular genetics.

[31]  Dimitri Krainc,et al.  Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease , 2002, Science.

[32]  Sawsan Youssef,et al.  Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine , 2002, Nature Medicine.

[33]  J. Cummings,et al.  Huntington's disease. , 1997, The Psychiatric clinics of North America.

[34]  Charles Kooperberg,et al.  Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. , 2002, Human molecular genetics.